Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, October 11, 2020

Carotid stent occlusion after emergent stenting in acute ischemic stroke: Incidence, predictors and clinical relevance

I can see massive problems with stenting your carotid artery. Why do it if your Circle of Willis is complete?

1. Occlusion

2. Trying to snake mechanical thrombectomy thru that stent to get to a clot in the brain.

3. Tying to pull a grabbed clot back thru the stent without ripping the artery completely open. 

I'm not medically trained, don't listen to me. But have your doctor GUARANTEE NO COMPLICATIONS EVER!

Carotid stent occlusion after emergent stenting in acute ischemic stroke: Incidence, predictors and clinical relevance

Highlights

  • •
    Stent thrombosis occurs in one fifth of the patients treated with acute stenting.
  • •
    Stent thrombosis is associated with specific procedural variables.
  • •
    Stent thrombosis is associated with poor clinical outcome.
  • •
    Further investigation of strategies aimed to prevent stent occlusion is needed.

Abstract

Background and aims

Emergent stent placement may be required during neurothrombectomy. Our aim was to investigate the incidence, predictors and clinical relevance of early extracranial carotid stent occlusion following neurothrombectomy.

Methods

We retrospectively analyzed a cohort of 761 consecutive neurothrombectomies performed at our center between May 2010 and August 2018, from whom a total of 106 patients had acute internal carotid artery occlusions. Early stent occlusion was defined as complete vessel occlusion within 24 h of neurothrombectomy. Clinical outcome was evaluated at day 90 with the modified Rankin Score scale (mRS). Pretreatment, procedural and outcome variables were recorded and analyzed using logistic regression.

Results

Carotid stenting was performed in 99 (13%) patients. Of those, 22 (22%) had early stent occlusion at follow-up. Stent occlusion was associated with a lower use of post-stenting angioplasty [adjusted OR (aOR) = 11.2, 95%CI = 2.49–50.78, p = 0.002)], increased residual intrastent stenosis (aOR = 2.1, 95%CI = 1.38–3.06, p < 0.001) and unsuccesful intracranial recanalization (modified TICI score 0-2a) (aOR = 13.5, 95%CI = 1.97–92.24, p = 0.008). Stent occlusion was associated with poor clinical outcome at day 90 (poorer mRS shift, aOR = 3.9, 95%CI = 1.3–11.3, p = 0.014; mRS>2, aOR = 6.3, 95%CI = 1.8–22.7, p = 0.005), and with an increased rate of symptomatic intracranial hemorrhage at 24 h (14% versus 1%, p = 0.033).

Conclusions

Early carotid stent occlusion occurred in one out of five neurothrombectomies and was associated with periprocedural factors that included increased residual intrastent stenosis, a lower use of post-stenting angioplasty and unsuccessful intracranial recanalization. Further investigation is warranted for the evaluation of strategies aimed to prevent carotid stent occlusion.

Graphical abstract

Physical activity and risk of Alzheimer disease: A 2-sample Mendelian randomization study

 

I have no fucking clue what this says. Your mentors and senior researchers need to be fired for allowing this to be published like this. 

Physical activity and risk of Alzheimer disease: A 2-sample Mendelian randomization study

Sebastian E. Baumeister, André Karch, Martin Bahls, Alexander Teumer, Michael F. Leitzmann, Hansjörg Baurecht

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective Evidence from observational studies for the effect of physical activity on the risk of Alzheimer disease (AD) is inconclusive. We performed a 2-sample mendelian randomization analysis to examine whether physical activity is protective for AD.

Methods Summary data of genome-wide association studies on physical activity and AD were used. The primary study population included 21,982 patients with AD and 41,944 cognitively normal controls. Eight single nucleotide polymorphisms (SNPs) known at p < 5 × 10−8 to be associated with average accelerations and 8 SNPs associated at p < 5 × 10−7 with vigorous physical activity (fraction of accelerations >425 milligravities) served as instrumental variables.

Results There was no association between genetically predicted average accelerations with the risk of AD (inverse variance weighted odds ratio [OR] per SD increment: 1.03, 95% confidence interval 0.97–1.10, p = 0.332). Genetic liability for fraction of accelerations >425 milligravities was unrelated to AD risk.

Conclusion The present study does not support a causal association between physical activity and risk of AD.

Activity-based training with the Myosuit: a safety and feasibility study across diverse gait disorders

What the fuck is your stroke hospital going to do with this? NOTHING?

Do you prefer your hospital incompetence NOT KNOWING? OR NOT DOING?

 

Activity-based training with the Myosuit: a safety and feasibility study across diverse gait disorders

Abstract

Background

Physical activity is a recommended part of treatment for numerous neurological and neuromuscular disorders. Yet, many individuals with limited mobility are not able to meet the recommended activity levels. Lightweight, wearable robots like the Myosuit promise to facilitate functional ambulation and thereby physical activity. However, there is limited evidence of the safety and feasibility of training with such devices.

Methods

Twelve participants with diverse motor disorders and the ability to walk for at least 10 m were enrolled in this uncontrolled case series study. The study protocol included five training sessions with a net training time of 45 min each. Primary outcomes were the feasibility of engaging in training with the Myosuit, the occurrence of adverse events, and participant retention. As secondary outcomes, we analyzed the walking speed using the 10-m Walk Test (10MWT) and for three participants, walking endurance using the 2-min Walk Tests.

Results

Eight out of 12 participants completed the entire study protocol. Three participants withdrew from the study or were excluded for reasons unrelated to the study. One participant withdrew because of an unsafe feeling when walking with the Myosuit. No adverse events occurred during the study period for any of the participants and all scheduled trainings were completed. For five out of the eight participants that completed the full study, the walking speed when using the Myosuit was higher than to their baseline walking speed.

Conclusions

Activity-based training with the Myosuit appears to be safe, feasible, and well-tolerated by individuals with diverse motor disorders.

Background

Physical inactivity has been identified as the fourth leading risk factor for global mortality, only surpassed by hypertension, tobacco use, and hyperglycemia. To contain the risks associated with physical inactivity, the World Health Organization recommends that all adults engage in moderate intensity physical activity for at least 150 min each week [1].

Physical activity is also a recommended part of treatment for stroke patients [2], and for patients with incomplete spinal cord injury (SCI) [3], inherited neuropathies such Charcot–Marie–Tooth disease [4], heart failure [5], or chronic obstructive pulmonary disease [6]. These wide-ranging recommendations reflect the consistent association between increased physical activity and improved health-related quality of life (e.g. [7,8,9].).

In spite of the evident health benefits of physical activity, a large proportion of elderly individuals and individuals with limited mobility do not meet the recommended dose of physical activity in their daily lives [10]. In many of these cases, neurological, neuromuscular, or cardiovascular deficits prevent individuals from reaching moderate intensity levels during exercise. In some cases, they prohibit any voluntary exercise altogether.

To address this problem, various technological solutions like full-leg, rigid exoskeletons have been developed to assist overground mobility (e.g. [11,12,13,14].). The safety and feasibility of gait training with mobile exoskeletons has been evaluated in several longitudinal training studies for individuals with spinal cord injury [15,16,17] and hemiparesis following stroke [18, 19]. Rigid exoskeletons largely substitute the ambulatory function of severely affected or completely paralyzed individuals and enable them to walk. Electric motors are used to provide large assistive torques to the users’ leg joints via rigid linkages. This allows exoskeletons to support the majority of the users’ weight and advance the users’ legs without a major voluntary contribution from the leg muscles.

The typically large masses of mobile rigid exoskeletons increase limb inertia and thereby hinder walking at higher speeds. The highest walking speed achieved in previous training studies [15,16,17,18,19] was 0.67 m/s, while most speeds were as low as 0.1 m/s to 0.4 m/s. This is well below the speeds required to support individuals with residual mobility during moderate intensity exercise.

To assist this more capable section of the population, more lightweight wearable robots (also known as “exosuits”, “exomuscles” or “dermoskeletons”) have been proposed [20,21,22,23,24]. Unlike exoskeletons that act on all leg joints, these devices allow for—and require—the active participation of the user, and can (partially) assist walking over a larger range of speeds [20, 25]. Thereby, such wearable robots can provide assistance as needed for functional ambulation [25] while simultaneously modulating the cardiovascular load of their users according to exercise recommendations. For example, a soft robotic exosuit unilaterally acting on one ankle joint was shown to reduce the energy expenditure and interlimb asymmetry of individuals with hemiparesis following a stroke during walking at 0.5 to 1.3 m/s [20]. In previous work from our group, we demonstrated that a soft wearable robot actively supporting hip and knee extension, the Myosuit, enabled an individual with incomplete SCI to walk substantially faster when assisted [25]. More recently, we showed that this functional improvement also translates to an increase in exercise intensity and a momentary reduction of the energetic cost of transport [26]. In larger longitudinal studies, training with wearable robots acting on the hip joint was shown to result in an intrinsic reduction of the cost of transport for elderly individuals [23] and individuals following stroke [24].

 

Saturday, October 10, 2020

Literature Review Explores Potential Neuroprotective Effects of Resveratrol

This doesn't seem to be using the word neuroprotection as it is used in stroke for stopping the neuronal cascade of death. So don't start demanding red wine from your doctor during the first week.

Literature Review Explores Potential Neuroprotective Effects of Resveratrol 

Systematic review data published in Advances in Medical Sciences provide mixed support for the benefits of resveratrol (RSV) in patients with neurodegenerative disorders. While RSV demonstrated neuroprotective effects in chemical and animal studies, few trials have assessed its use in patients at risk for Alzheimer disease.

Investigators at the Medical University of Warsaw in Poland conducted a systematic review of PubMed for experimental and clinical studies of RSV published within the last 10 years. Articles describing the pathology of Alzheimer disease and its relationship to RSV were selected. Investigators provided a summary of the literature data and commentary on RSV’s role in neurodegenerative disease prevention.

RSV is a natural phenol produced by over 70 plant species, including grapes, blueberries, cranberries, and peanuts. It has been widely studied for its antioxidant and anti-inflammatory effects. While the exact mechanism of Alzheimer disease is unclear, research suggests that oxidative stress is closely related to its development. RSV has been shown to inhibit cyclooxygenase-2 (COX-2), thus preventing oxidative damage from free radicals. RSV can also decrease the activity of tumor necrosis factor (TNF)-alpha and interleukin-1 (IL-1), leading to substantial anti-inflammatory properties. Antioxidative and anti-inflammatory effects may have implications for Alzheimer disease treatment, though further research is necessary to interpret changes in these biomarkers during treatment with RSV.

In in vitro studies, RSV was found to destabilize amyloid aggregates and inhibit the production of amyloid ß protein (Aß). Increased Aß levels correlate with cognitive decline in patients with Alzheimer disease, and Aß aggregation and accumulation are considered key risk factors for dementia. Demonstrated in 3 studies, RSV inhibits the formation of Aß-aggregates by activating the deacetylase sirtuin 1 (SIRT1) gene. RSV also promotes the tau protein demethylation and dephosphorylation. Tau proteins, like Aß, are associated with cognitive decline. By promoting effective degradation of tau proteins, RSV may prevent the formation of aggregates associated with Alzheimer disease.

Today’s Top Picks for You on Neurology Advisor

Continue Reading

While in vitro and in vivo studies support RSV’s protective effects, its low solubility and bioavailability limit its efficacy in humans. Efforts to increase its bioavailability include nanoencapsulation in other structure and methoxylation or hydroxylation of the RSV aromatic rings. Further study is necessary to assess the impact of these methods on RSV’s uptake. Additionally, placebo-controlled clinical trials are necessary to better elucidate the neuroprotective effect of RSV in humans. Appropriate RSV recipients may include patients with a family history of Alzheimer disease, or patients with Alzheimer disease in its early stages.

“RSV mechanisms of action indicate that it could be used in [Alzheimer disease] prevention, especially in reference to some familial forms of AD,” the investigators wrote. “The main limitations referring to such presumption include: limited [bioavailability]…and scarcity of clinical studies on RSV pertaining to large groups of humans.”

Reference

Komorowska J, Wątroba M, Szukiewicz D. Review of beneficial effects of resveratrol in neurodegenerative diseases such as Alzheimer’s disease. Adv Med Sci. 2020;65(2):415-423.

This article originally appeared on Psychiatry Advisor

 

Heparin Induced Thrombocytopenia in Severe COVID-19 Patients

No abstract, but my takeaway from this is the word severe, which to me means immediate heparin upon diagnosis.

You see a doctor immediately and get anti-coagulation going. You don't wait until it gets severe before you see a doctor. I'm going to demand heparin. Don't tough it out at home.

 Heparin binds to cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and "potently" blocks the virus, which could open up therapy options.

Anticoagulation Again Shown to Improve Survival in COVID-19 Patients;-Mortality risk about 50% lower

Stroke occurs frequently in COVID-19, leads to ‘devastating consequences’ for patients


I'm not medically trained so I know nothing, don't listen to me.

The latest here:

Heparin Induced Thrombocytopenia in Severe COVID-19 Patients

82% of Hospitalized COVID-19 Patients Had Neurologic Symptoms

You see a doctor immediately and get anti-coagulation going. You don't wait until it gets severe before you see a doctor. I'm going to demand heparin. Don't tough it out at home.

 Heparin binds to cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and "potently" blocks the virus, which could open up therapy options.

Anticoagulation Again Shown to Improve Survival in COVID-19 Patients;-Mortality risk about 50% lower

Stroke occurs frequently in COVID-19, leads to ‘devastating consequences’ for patients


I'm not medically trained so I know nothing, don't listen to me.

The latest here:

82% of Hospitalized COVID-19 Patients Had Neurologic Symptoms

Nearly one-third showed encephalopathy in major U.S. healthcare system

A woman wearing a protective mask with her eyes closed and hand on her forehead

More than 80% of hospitalized COVID-19 patients had neurologic symptoms during their disease course, a retrospective Chicago-area study showed.

Neurologic manifestations were present at COVID-19 onset in 42.2% of 509 consecutive hospitalized COVID-19 patients, at hospitalization in 62.7%, and at anytime during the disease course in 82.3%, reported Igor Koralnik, MD, of Northwestern Medicine in Chicago, and colleagues in the Annals of Clinical and Translational Neurology.

Myalgia (44.8%), headache (37.7%), encephalopathy (31.8%), and dizziness (29.7%) were the most frequent neurologic manifestations, followed by dysgeusia (15.9%) and anosmia (11.4%).

Patients presenting with neurologic symptoms were younger than those who didn't have symptoms. Most patients with neurologic manifestations had a favorable functional outcome at discharge, but encephalopathy -- which affected nearly one in three patients -- was associated with increased morbidity and mortality, independent of respiratory disease severity.

"This is the first study in the U.S. of the prevalence of neuro manifestations in a large population of hospitalized patients," Koralnik told MedPage Today. Only two other papers describing the prevalence of neurological manifestations in hospitalized COVID-19 patients have been published: one based in China, the other in Spain.

Neurological complications of COVID-19 are frequent and in many cases long-lasting, but have not yet received much attention, noted Avindra Nath, MD, senior investigator of nervous systems infections at the NIH National Institute of Neurological Disorders and Stroke, who wasn't involved with the study.

"While it is not unexpected that the sickest patients would have the most neurological complications, it is surprising that these manifestations occur more commonly in younger individuals and is independent of the severity of respiratory involvement," Nath told MedPage Today.

The study's retrospective nature may mean the frequency of neurologic manifestations is underreported, he pointed out.

In their study, Koralnik and colleagues retrospectively analyzed the first 509 consecutive patients admitted with COVID‐19 to the Northwestern Medicine Healthcare system between March 5 and April 6. The Northwestern Medicine system consists of one academic medical center and nine other hospitals in the Chicago area.

COVID‐19 diagnosis was confirmed by SARS‐CoV‐2 reverse transcription‐polymerase chain reaction (RT‐PCR) assay. Encephalopathy was identified by report of altered mental status or depressed level of consciousness, physician-documented diagnosis of encephalopathy or delirium encephalopathy syndrome, or positive Confusion Assessment Method evaluation.

Functional outcome at hospital discharge was based on modified Rankin Scale (mRS), a six-point disability scale in which scores of 0-2 mean a patient can look after his or her own affairs without assistance and 6 represents death.

Patients were age 58.5 on average and 55.2% were men; 134 patients (26.3%) had severe COVID‐19 requiring mechanical ventilation. In total, 419 of the 509 patients had neurologic manifestations at any time during the disease course. Independent risk factors for developing any neurologic manifestation were severe COVID‐19 (OR 4.02, 95% CI 2.04–8.89, P<0.001) and younger age (OR 0.982, 95% CI 0.968–0.996, P=0.014).

Strokes, movement disorders, motor and sensory deficits, ataxia, and seizures were uncommon (0.2 to 1.4% of patients each). Overall, 71.1% of hospitalized COVID-19 patients with neurologic symptoms were discharged with an mRS score of 0-2.

Hospitalized COVID-19 patients with encephalopathy were older than those without (66 vs 55 years, P<0.001), had a shorter time from COVID onset to hospitalization (6 vs 7 days, P=0.014), were more likely to be male, and to have a history of any neurological disorder, cancer, cerebrovascular disease, chronic kidney disease, diabetes, dyslipidemia, heart failure, hypertension, and smoking in assessments without multivariate adjustment.

"Triggers were likely multifactorial, including systemic disease -- multi-organ failure, coagulopathy, inflammation -- or direct infection of the brain by the virus, or post-infectious autoimmune mechanisms," Koralnik said.

Patients with encephalopathy had a median hospital stay of 17 days, while those without encephalopathy stayed a median of 5 days. At hospital discharge, 32.1% of patients with encephalopathy had an mRS score of 0-2, compared with 89.3% of those who did not develop encephalopathy.

Encephalopathy independently was associated with worse functional outcome (OR 0.22, 95% CI 0.11–0.42, P<0.001) and higher mortality within 30 days of hospitalization (21.7% vs 3.2%, P<0.001).

Overall, there was no meaningful difference in COVID-19 severity between patients at the academic medical center and ones at the nine other hospitals, but patients at the academic center had better functional outcomes and lower 30-day mortality.

"It's of concern that the outcome of patients was different in the various hospitals," Nath said. "The authors attribute this to differences in the quality of care provided. This means that hospitalized patients require high level of care which is not available in most places and points to an important vulnerability of our healthcare system."

The study had several limitations, including its retrospective nature and the fact that fewer than 6% of patients were evaluated by neurologists or neurosurgeons. With strict infection control precautions in place, access to brain CT or MRI was limited, the researchers said.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

Researchers disclosed no relevant relationships with industry.

 

HonorHealth Rehabilitation Hospital(Scottsdale,AZ) Earns Four Prestigious CARF Accreditations

 

Big fucking whoopee.

I couldn't find any stroke standards at the CARF website - http://www.carf.org/home/
so with nothing public, this is completely fucking worthless. Because if this is all just doing processes with no measurement of results, then useless.

Three measurements will tell me if the stroke hospital is possibly not completely incompetent; DO YOU MEASURE ANYTHING? This is just hiding.

  1. tPA full recovery? Better than 12%?

  1. 30 day deaths? Better than competitors?

  1. rehab full recovery? Better than 10%?


You'll' want to know results so Call that hospital president( Whoever that is?)
and demand to know what the RESULTS are; tPA efficacy, 30 day deaths, 100% recovery. Because there is no point in going to that hospital if they are not willing to publish results.

The latest invalid chest thumping here:

HonorHealth Rehabilitation Hospital(Scottsdale,AZ) Earns Four Prestigious CARF Accreditations

HonorHealth Rehabilitation Hospital, a joint venture partnership between Select Medical and HonorHealth, announced today that it has received the Commission on Accreditation of Rehabilitation Facilities' (CARF) accreditation for the hospital, as well as specialty certifications for its stroke, brain injury and amputation programs. The prestigious accreditation marks a provider's commitment to continually enhance the quality of services and programs with a focus on patient satisfaction and outcomes.

CARF's three-year accreditation represents the highest level of certification that a rehabilitation hospital can receive. The earned honor is based on a rigorous peer review process involving an interdisciplinary team of surveyors who typically conduct a series of on-site visits, but due to COVID-19 restrictions, the review was completed virtually over a three-day period. The surveyors evaluate a hospital's commitment to offering programs and services that are measurable, accountable and high quality. The surveyors also take a deep look at a range of elements – including all aspects of patient care, programs and services offered, staff engagement, customer service, hospital culture and leadership – to inform their review.

"We are incredibly proud to have achieved CARF accreditation for HonorHealth Rehabilitation Hospital including specialty certifications for stroke, brain injury and amputation. CARF confirms HonorHealth Rehabilitation Hospital's commitment to continually enhance the quality of our services and programs with a focus on the satisfaction of patients," said Scott Keen, chief executive officer at HonorHealth Rehabilitation Hospital. "This is a meaningful achievement for both our staff and the community we serve. Our dedicated teams strive to achieve our mission and core values every day by delivering superior quality and compassion to our patients in their healing and recovery."

HonorHealth Rehabilitation Hospital is a 50-bed facility that provides rehabilitation services for patients in need of general rehabilitation or who have suffered from stroke, brain and spinal cord injuries, amputations, neurological disorders, orthopedic issues and Parkinson's disease. 

About CARF
CARF is an independent, nonprofit accrediting body whose mission is to promote the quality, value, and optimal outcomes of services through a consultative accreditation process and continuous improvement services that center on enhancing the lives of persons served.

About HonorHealth
HonorHealth is a non-profit, local community healthcare system serving an area of 1.6 million people in the greater Phoenix area. The network encompasses six acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer care network, clinical research, medical education, a foundation and community services with approximately 12,300 employees, 3,700 affiliated physicians and 3,100 volunteers. HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth's mission is to improve the health and well-being of those we serve. Learn more at http://www.HonorHealth.com.

 

The Minimal Clinically Important Difference for Achievement of Substantial Reperfusion With Endovascular Thrombectomy Devices in Acute Ischemic Stroke Treatment

Once again having the completely wrong endpoint to be measured, reperfusion, rather than 100% recovery.

The Minimal Clinically Important Difference for Achievement of Substantial Reperfusion With Endovascular Thrombectomy Devices in Acute Ischemic Stroke Treatment

  • 1Neurological Institute, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
  • 2Comprehensive Stroke Center and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Background and Purpose: Recent noninferiority clinical trials of novel endovascular thrombectomy devices for acute ischemic stroke have used substantial reperfusion as the primary outcome of achievement. Determining the minimal clinically important difference (MCID) is an essential step for the design of noninferiority clinical trials.

Materials and Methods: We surveyed international neuro-interventionalist and noninterventional vascular neurologist investigators. The questionnaire included demographic characteristics, level of clinical experience, and their MCID clinical scenario-based judgment regarding the MCID for the outcome substantial reperfusion (thrombolysis in cerebral infarction score 2b-3) within 3 passes.

Results: Survey responses were received from 58 of 200 experts. Among responders, 75.9% were neuro-interventionalists (most commonly interventional neuroradiologists and interventional neurologists, followed by endovascular neurosurgeons), and 24.1% were noninterventional vascular neurologists; 87.9% had been in practice for more than 5 years, and 67.3% devoted more than half of their practice to stroke care. Responder–nonresponder and continuum of resistance analysis indicated responders were representative of the full expert population. Among experts, the median MCID for substantial reperfusion was 3.1–5% (interquartile range 1.1–3% to 5.1–10%). MCID distributions did not differ among neuro-interventionalists and noninterventional vascular neurologists.

Conclusions: Neuro-interventionl and noninterventional stroke experts judged that the minimal clinically important difference in comparing thrombectomy devices for achieving substantial reperfusion is 3.1–5%. This MCID, lower than noninferiority margins used in several recent clinical trials, can inform trial designs and clinical development.

The appropriate clinical trial designs to assess device treatments for a disease may be divided into four broad types, based on 2 types of endpoint and 2 types of design. The two types of primary endpoints are (1) technical efficacy endpoints, used when the trial is assessing the device's effectiveness as a tool (does it do what it says?), and (2) clinical efficacy endpoints when the trial is assessing the device's effectiveness as a care strategy (does the patient have a better final health state as a result?). The two types of designs are (1) superiority clinical trials, in which a novel device is tested to determine if it yields better technical or clinical outcomes than a standard device or medical therapy alone, and (2) noninferiority clinical trials, in which a novel device is tested to determine if it yields technical or clinical outcomes at least as good as a standard device or medical therapy alone.

Trials using technical, rather than clinical, efficacy outcomes may be of particular importance at early and at final stages in the initial development of a device class and use case. Early in device development, iterative innovation in device design to optimize its technical performance is a leading concern. Once device designs are sufficiently mature, it is desirable to perform superiority trials against older care strategies not using the device class to demonstrate that using the device class does ultimately improve the final clinical outcomes of patients. When a device class has been shown to have clinical utility, further novel, within-class devices may often be adequately assessed again with the use of technical efficacy primary endpoints. At this stage, when the device class has already attained a generally high level of technical performance success, noninferiority trials with technical efficacy endpoints are useful, in which novel device variations are shown to be at least as good as existing, approved devices.

The development of endovascular thrombectomy (EVT) devices for acute ischemic stroke due to large vessel occlusion (AIS-LVO) has recently generally followed this trajectory. A wave of several superiority design trials were first performed and demonstrated the superiority of endovascular thrombectomy over medical therapy alone (1–9). Thereafter, trials assessing successor variations in thrombectomy device design have generally used noninferiority designs, seeking to demonstrate that newer devices are at least as good as existing devices (10–12).

For noninferiority clinical trial design, even more so than for superiority clinical trial design, determining the minimal clinically important difference (MCID) in an outcome is a crucial, and challenging, step that affects trial power. The MCID is the smallest change in a disease outcome that a patient and/or a care provider would identify as worthwhile (13). For superiority trials, seeking to determine if new treatment A is better than conventional treatment B, the MCID establishes the threshold difference at which superiority can be declared. If treatment A yields an incremental increase in favorable outcomes that exceeds the MCID, then superiority is established. For noninferiority and equivalence trials, the MCID establishes the threshold value (“margin”) at which noninferiority or equivalence can be declared. If treatment A does not yield an incremental increase in favorable outcomes that exceeds the MCID, then noninferiority is established. For both superiority and noninferiority/equivalence trials, requisite sample size is inversely related to the amplitude of the MCID. The smaller the MCID for a particular outcome, the larger a trial must be in order to be adequately powered to determine if a novel treatment exceeds or does not exceed that threshold.

However, for EVT treatment of AIS-LVO, the MCID has not been formally established for the most commonly employed technical efficacy outcome: achieving substantial reperfusion (i.e., achieving a thrombolysis in cerebral infarction, TICI, scale score of 2b-3). During the conduct of a recent noninferiority meta-analysis of randomized trials comparing different EVT techniques, a systematic literature search identified two expert survey studies characterizing the MCID for the clinical efficacy outcome of functional independence (modified Rankin Scale 0–2) at 3 months but no expert survey study characterizing the MCID for the technical efficacy outcome of achievement of substantial reperfusion (14). The current study was, therefore, undertaken to provide that desirable additional frame.

Approaches to establishing the MCID for a particular outcome are of 3 broad types: Delphi expert–based approaches, anchor-based approaches, and distribution-based approaches (15). For an acute-onset disease such as stroke, the Delphi expert–based approach is generally preferred (16), especially for a technical efficacy outcome such as reperfusion, which requires technical expertise to appreciate, rather than patient-level subjective experience of a disease state. Therefore, we undertook a Delphi-expert survey study of leading international neuro-interventionalists and noninternventional vascular neurologists to the MCID of achieving substantial reperfusion with endovascular thrombectomy devices in patients with AIS-LVO.

 

Amniotic fluid may yield new, better treatment for ischemic stroke

Interesting, but nothing will be done with it. We have NO STROKE LEADERSHIP. 

But better than these? And why just ischemic stroke?

Amniotic fluid may yield new, better treatment for ischemic stroke

Durham, NC - A study released today in STEM CELLS Translational Medicine points the way to a possible new avenue of treatment for ischemic stroke. The study, led by Annamaria Cimini, Ph.D., of the University of L'Aquila, and Liborio Stuppia, M.D., of D'Annunzio University, Italy, reveals how the secretome of amniotic fluid stem cells can restore neuronal plasticity (the brain's capacity to change and adapt), improve cognition, and replace neurons damaged or lost due to an ischemic stroke.

Their finding may lead to a more broadly applicable stroke therapy that is not hindered by a narrow treatment window or pre-existing conditions.

Each year, 5.5 million people across the world die from stroke, and more than 116 million years of healthy life are lost due to stroke-related death and disabilities, according to the World Stroke Organization. Most strokes - an estimated 87 percent - are the ischemic type, which occur when a vessel supplying blood to the brain becomes obstructed.

The most effective treatment currently in use is a clot-busting drug known as a tissue plasminogen activator (t-PA). However, to be effective the t-PA must be given within three hours after the onset of stroke symptoms, and even then the cure rate is just one in 10 patients. t-PAs also have their own risks, especially for people who have a history of bleeding problems, uncontrolled high blood pressure, or recent surgery or trauma.

"Thrombolytic therapy itself can lead to brain injuries, namely cerebral ischemia/reperfusion (I/R) injury. I/R injury is one of the major reasons for disability, high morbidity, and mortality worldwide," Dr. Cimini said. (Reperfusion refers to the act of restoring the flow of blood to an organ or tissue, typically after a heart attack or stroke.)

In the search for better treatment options, stem cells have emerged as a possible candidate due to their regenerative abilities. Human amniotic fluid stem cells (hAFSCs) in particular are interesting, as adult stem cells - even after reprogramming - might pass along any pre-existing genetic conditions, thus representing a limitation in their application.

On the other hand, hAFSCs offer a clean therapeutic slate. A novel class of pluripotent stem cells with intermediate characteristics between embryonic and adult stem cells, hAFSCs are able to safely differentiate into all types of tissue. Furthermore, ethical issues related to their use are minimal, as they are collected during routine amniocentesis, third-trimester amnio-reduction or Cesarean section.

The growing interest in hAFSCs over the past decade has led researchers to also investigate the cells' secretome - which encompasses the complete set of proteins expressed by cells and secreted into the extracellular space - and its potential neuroprotective mechanisms.

In their current study, the Cimini- Stuppia team wanted to determine which signal transduction pathways might be activated by hAFSC-derived secretome during a stroke. (Signal transduction is how signals are transferred through a cell via proteins - a process necessary for healing.) They also wanted to analyze miRNA expression in the conditioned medium. miRNAs found in exosomes are key regulators of the immune response that affect maturation, proliferation, differentiation and activation of immune cells, as well as antibody secretion and release of inflammatory mediators.

"Thus, exosomes offer an alternative therapeutic approach as a substitute for cell transplantation," Dr. Cimini said.

The team began by first devising an in vitro stroke model. To do this, they deprived hAFSCs of oxygen and glucose for a three hour period after testing several different time windows - at three hours, the cells showed a reduction in viability of about 50 percent. Then, 24 hours later, they treated the oxygen/glucose depleted cells with several different percentages of hAFSC-conditioned medium.

"When we examined the results, we found that the hAFSC-derived secretome had activated pro-survival pathways, as well as pathways that halted apoptosis (programmed cell death). Furthermore, microRNA analysis in the exosomal component revealed an abundance of miRNAs involved in protecting neurons and controlling neuronal cell death," Dr. Stuppia reported.

"In light of the data obtained, we believe that the use of conditioned medium and, in particular, exosomes may represent a suitable treatment for I/R injury," he concluded.

"These early pre-clinical results are certainly encouraging and demonstrate the need to further pursue human amniotic fluid stem cells-derived secretome as a regenerative cell therapy," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "These outcomes suggest a potential approach that could change the outcome for millions of patients who suffer a stroke."

###

The full article, "Neuroprotective Effects of Human Amniotic Fluid Stem Cells-Derived Secretome in an Ischemia/Reperfusion Model," can be accessed at https:/>/stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.20-0268.